Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PYD001
MIFTS: 54

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pyoderma Gangrenosum

About this section

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 74 52 58 54 15 17 71 32

Characteristics:

Orphanet epidemiological data:

58
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8553
ICD9CM 34 686.01
SNOMED-CT 67 74578003
ICD10 32 L88
MESH via Orphanet 44 D017511
ICD10 via Orphanet 33 L88
UMLS via Orphanet 72 C0085652
Orphanet 58 ORPHA48104
UMLS 71 C0085652
Sources

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases : 52 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis , Crohn's disease , polyarthritis (an inflammation of several joints together), gammopathy , vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses . Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics , corticosteroids , immunosuppressants, and biologics.

MalaCards based summary : Pyoderma Gangrenosum is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and crohn's disease. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Minocycline and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related phenotypes are fever and arthralgia

Wikipedia : 74 Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Sources

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 713)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 33.1 SIGLEC5 PSTPIP1 NLRP3 MVK MEFV IL1RN
2 crohn's disease 31.8 TNFRSF1B TNF NOD2 NLRP3 CXCL8 CCR6
3 colitis 31.4 TNF NOD2 CXCL8 CCR6
4 neutrophilic dermatosis, acute febrile 31.4 MEFV CSF3
5 erythema elevatum diutinum 31.1 PSTPIP1 CXCL8
6 myelofibrosis 31.0 TNF IFNA2 CXCL8 CSF3
7 cellulitis 30.9 TNF IL1R1 CCR6
8 fasciitis 30.9 TNF IL1RN CXCL8
9 crohn's colitis 30.9 TNF NOD2 CXCL8 CCR6
10 vasculitis 30.9 TNFRSF1B TNF MEFV ITGB2 IFNA2 APOH
11 sclerosing cholangitis 30.8 TNF NOD2 CXCL8
12 purpura 30.8 TNF MEFV F3 APOH
13 dermatitis 30.8 TNF NOD2 CXCL8 CCR6
14 cyclic neutropenia 30.8 TNF CXCL8 CSF3
15 antiphospholipid syndrome 30.8 TNF F3 APOH
16 cryoglobulinemia 30.8 TNF IFNA2 APOH
17 cholangitis 30.7 TNF NOD2 F3 CXCL8
18 granulomatous dermatitis 30.7 TNFRSF1B TNF NOD2
19 polyarteritis nodosa 30.6 MEFV IFNA2 APOH
20 acute graft versus host disease 30.6 TNF NOD2 CSF3
21 vascular disease 30.6 TNF MMP9 F3 CSF3 APOH
22 diverticulitis 30.6 TNF MMP9 CCR6
23 leukocyte adhesion deficiency, type i 30.5 ITGB2 CSF3 CCR6
24 lung disease 30.5 TNF MMP9 F3 CXCL8 CSF3
25 intestinal disease 30.5 TNF NOD2 CXCL8 CCR6
26 hepatitis a 30.5 TNF IFNA2 F3 CXCL8
27 ulcerative colitis 30.5 TNF NOD2 IL1RN IL1R1 CXCL8 CCR6
28 myeloma, multiple 30.4 TNF MMP9 CXCL8 CSF3 CCR6
29 acute cystitis 30.4 TNF CXCL8 CCR6
30 keratitis, hereditary 30.4 TNF NLRP3 CCR6
31 proctitis 30.3 TNF NOD2 CCR6
32 varicose veins 30.3 TNF MMP9 CXCL8
33 ileitis 30.3 TNF NOD2 CCR6
34 neutropenia 30.2 TNF IL1RN IFNA2 CXCL8 CSF3
35 pouchitis 30.2 NOD2 IL1RN CXCL8
36 skin disease 30.2 TNFRSF1B TNF SIGLEC5 ITGB2 CXCL8 CCR6
37 endometritis 30.2 TNF SIGLEC5 CXCL8
38 syphilis 30.2 TNF CCR6 APOH
39 diarrhea 30.2 TNF NOD2 MVK MEFV IFNA2 CXCL8
40 hemolytic anemia 30.1 TNF IFNA2 F3 CSF3 APOH
41 histoplasmosis 30.1 TNFRSF1B TNF CCR6
42 vaginitis 30.1 TNF CXCL8 CCR6
43 peptic ulcer disease 30.1 TNF IL1RN CXCL8
44 synovitis 30.1 TNF MMP9 IL1RN CXCL8
45 limb ischemia 30.0 TNF SIGLEC5 MMP9
46 essential thrombocythemia 30.0 TNF IFNA2 F3 CXCL8 CSF3
47 aortitis 30.0 TNFRSF1B TNF IL1RN
48 common variable immunodeficiency 30.0 TNFRSF1B TNF NOD2 IL1R1
49 chickenpox 30.0 TNFRSF1B TNF CCR6
50 chronic recurrent multifocal osteomyelitis 29.9 TNF PSTPIP1 NLRP3 MEFV IL1RN

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum
Sources

Symptoms & Phenotypes for Pyoderma Gangrenosum

About this section

Human phenotypes related to Pyoderma Gangrenosum:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
3 papule 58 31 hallmark (90%) Very frequent (99-80%) HP:0200034
4 skin ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0200042
5 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
6 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
7 inflammation of the large intestine 58 31 frequent (33%) Frequent (79-30%) HP:0002037
8 myelodysplasia 58 31 frequent (33%) Frequent (79-30%) HP:0002863
9 pustule 58 31 frequent (33%) Frequent (79-30%) HP:0200039
10 rheumatoid arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001370
11 atrophic scars 58 31 frequent (33%) Frequent (79-30%) HP:0001075
12 myeloid leukemia 58 31 frequent (33%) Frequent (79-30%) HP:0012324
13 increased circulating antibody level 31 frequent (33%) HP:0010702
14 abnormal blistering of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0008066
15 skin vesicle 58 31 occasional (7.5%) Occasional (29-5%) HP:0200037
16 increased antibody level in blood 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CXCL8 NLRP3 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 APOH CXCL8 NLRP3 NOD2 TNF TNFRSF1B

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CCR6 CSF3 F3 IL1R1 IL1RN ITGB2
2 immune system MP:0005387 9.77 CCR6 CSF3 F3 IL1R1 IL1RN ITGB2
3 integument MP:0010771 9.32 CSF3 F3 IL1R1 IL1RN ITGB2 MEFV
Sources

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
2
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
3 Anti-Bacterial Agents Phase 3
4 Anti-Infective Agents Phase 3
5 Anti-Inflammatory Agents Phase 2, Phase 3
6 Antirheumatic Agents Phase 2, Phase 3
7 Pharmaceutical Solutions Phase 3
8 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
9
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
10 Dermatologic Agents Phase 2
11 Immunosuppressive Agents Phase 2
12 Calcineurin Inhibitors Phase 2
13 Immunologic Factors Phase 2
14 Immunoglobulins Phase 2
15 Antibodies Phase 2
16 Antibodies, Monoclonal Phase 2
17
Infliximab Approved 170277-31-3
18 sodium fluoride Approved 7681-49-4
19 Gastrointestinal Agents
20 Fluorides
21 Listerine

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
2 A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan Completed NCT03311464 Phase 3 adalimumab
3 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
6 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
7 An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
8 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
9 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
10 Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
11 A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
12 Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum Recruiting NCT03971643 Phase 2 IFX-1
13 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Active, not recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
14 The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Not yet recruiting NCT04274166 Phase 2 secukinumab 150 mg (2 injections per dose
15 A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
16 A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) Withdrawn NCT00690846 Phase 2 adalimumab
17 Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
18 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Unknown status NCT01952275
19 Cutaneous JAK Expression in Vitiligo and Acne Vulgaris. Unknown status NCT03185312
20 An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum Completed NCT00791557 Infliximab
21 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Completed NCT00933296
22 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease Completed NCT00487396
23 A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data Recruiting NCT02280733
24 Genetics and Pathophysiology of Autoinflammatory Disorders. Recruiting NCT00001373
25 Chronic Recurrent Multifocal Osteomyelitis - Search for a Bacterial Cause and Improving Imaging With PET/MRI Recruiting NCT03433287
26 Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015 Not yet recruiting NCT03636737

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clofazimine
SULFAPYRIDINE PWDR
Sources

Genetic Tests for Pyoderma Gangrenosum

About this section
Sources

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

40
Skin, Neutrophil, Breast, Myeloid, T Cells, Lung, Bone
Sources

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 3067)
# Title Authors PMID Year
1
Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. 61 54
19700023 2009
2
Pyrin Modulates the Intracellular Distribution of PSTPIP1. 54 61
19584923 2009
3
PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. 61 54
19290936 2009
4
The inherited autoinflammatory syndrome: a decade of discovery. 54 61
19768193 2009
5
Autoinflammatory diseases: clinical and genetic advances. 61 54
18347298 2008
6
Autoinflammatory gene mutations in Behçet's disease. 54 61
17213252 2007
7
The systemic autoinflammatory diseases: inborn errors of the innate immune system. 54 61
16724804 2006
8
Autoinflammatory syndromes. 61 54
16466630 2006
9
Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. 61 54
15916580 2005
10
A common pathway in periodic fever syndromes. 61 54
15324736 2004
11
CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. 61 54
15102098 2004
12
Isavuconazonium for the treatment of Purpureocillium lilacinum infection in a patient with pyoderma gangrenosum. 61
32547913 2020
13
Pyoderma gangrenosum and suppurative hidradenitis association, overlap or spectrum of the same disease? Case report and discussion. 61
32508990 2020
14
Expert Commentary on the Management of Peristomal Pyoderma Gangrenosum in a Patient With IBD. 61
32496329 2020
15
Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. 61
32320362 2020
16
The Management of Peristomal Pyoderma Gangrenosum in IBD. 61
32496328 2020
17
Pyoderma gangrenosum associated with chronic recurrent multifocal osteomyelitis as a possible paradoxical reaction to anti-tumor necrosis factor-α therapy. 61
32515066 2020
18
Pyoderma gangrenosum in hematologic malignancies: A systematic review. 61
31560977 2020
19
Pyoderma gangrenosum of the eyelid associated with inflammatory bowel disease. 61
32195439 2020
20
Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status. 61
32548138 2020
21
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. 61
32383278 2020
22
The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. 61
32350817 2020
23
Neutrophilic dermatosis of the dorsal hands triggered by mechanical trauma. 61
32534462 2020
24
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. 61
32347562 2020
25
Pyoderma Gangrenosum and Superimposed Infection: A Case Report. 61
32427793 2020
26
A Wound Care Specialist's Approach to Pyoderma Gangrenosum. 61
32320358 2020
27
Negative Pressure Wound Therapy in Pyoderma Gangrenosum Treatment. 61
32520925 2020
28
Cutaneous Manifestations of Granulomatosis with Polyangiitis: A Case Series Study. 61
32374410 2020
29
Sunitinib-induced pyoderma gangrenosum-like skin ulcer. 61
32452467 2020
30
Retraction statement: Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich Syndrome. 61
32545926 2020
31
Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone. 61
31729012 2020
32
Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach. 61
32518053 2020
33
Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review. 61
32447747 2020
34
Pyoderma gangrenosum confused with congenital preauricular fistula infection: A case report. 61
32420301 2020
35
PG-TIME: A practical approach to the clinical management of pyoderma gangrenosum. 61
32291879 2020
36
Case of pyoderma gangrenosum with visceral involvement: severely recurrent disease with lung, spleen, mesorectum and subcutaneous tissue involvement. 61
32426955 2020
37
Novel Therapeutic Approaches and Targets for Treatment of Neutrophilic Dermatoses. 61
32359335 2020
38
Ileostomy adenocarcinoma in Crohn's disease. 61
32144530 2020
39
Is Gout Associated with Pyoderma Gangrenosum? A Population-Based Case-Control Study. 61
32481527 2020
40
Disseminated histoplasmosis presenting as pyoderma gangrenosum-like ulcers in an apparently immunocompetent patient: multiple red herrings presenting a diagnostic challenge. 61
32406079 2020
41
Pyoderma gangrenosum associated with ulcerative colitis: A recalcitrant case responded to adalimumab with granulocyte and monocyte adsorption apheresis. 61
32162361 2020
42
Pyoderma gangrenosum: From historical perspectives to emerging investigations. 61
32378319 2020
43
Peristomal pyoderma gangrenosum: Report on 11 cases. 61
32441368 2020
44
Herpes simplex infection mimicking classical pyoderma gangrenosum. 61
31956978 2020
45
Ulcerative pyoderma gangrenosum associated with cocaine use. 61
31113658 2020
46
Pyoderma gangrenosum after cardiac surgery. 61
32365430 2020
47
Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. 61
32445742 2020
48
[Neutrophilic and pustular dermatoses : New autoinflammatory diseases and syndromes]. 61
32303815 2020
49
Pediatric facial pyoderma gangrenosum preceding the diagnosis of inflammatory bowel disease. 61
32342563 2020
50
Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. 61
32318735 2020
Sources

Variations for Pyoderma Gangrenosum

About this section
Sources

Expression for Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.
Sources

Pathways for Pyoderma Gangrenosum

About this section

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.65 TNFRSF1B TNF SIGLEC5 PSTPIP1 NOD2 NLRP3
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.13 TNFRSF1B TNF NOD2 MMP9 ITGB2 IL1RN
3
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.49 TNF NOD2 NLRP3 IL1RN IL1R1 IFNA2
4
Shigellosis 36
12.31 TNF NLRP3 IL1R1 CXCL8
5
IL-17 Family Signaling Pathways 64
Show member pathways
 12.25 TNF MMP9 CXCL8 CSF3
6
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.25 TNFRSF1B TNF CXCL8 CCR6
7
Pathogenic Escherichia coli infection 36
12.18 TNF NLRP3 IL1R1 CXCL8
8
Tuberculosis 36
12.14 TNF NOD2 ITGB2 IFNA2
9
Yersinia infection 36
11.93 TNF NLRP3 MEFV CXCL8
10
Spinal Cord Injury 1
11.92 TNF MMP9 IL1R1 CXCL8
11
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 65
Show member pathways
 11.89 PSTPIP1 NOD2 NLRP3 MEFV
12
TNF signaling pathway 36
11.86 TNFRSF1B TNF NOD2 MMP9
13
Interleukin-4 and 13 signaling 65
11.82 TNFRSF1B TNF MMP9 ITGB2 CXCL8
14
Amoebiasis 36
11.8 TNF ITGB2 IL1R1 CXCL8
15
NOD-like receptor signaling pathway 36
11.76 TNF PSTPIP1 NOD2 NLRP3 MEFV IFNA2
16
Innate Lymphoid Cells Differentiation 64
11.71 TNF IL1R1 CCR6
17
Pertussis 36
11.64 TNF NLRP3 ITGB2 CXCL8
18
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.58 TNF MMP9 CXCL8
19
Lung fibrosis 1
11.53 TNF MMP9 CXCL8 CSF3
20
Legionellosis 36
11.52 TNF ITGB2 CXCL8
21
Transcription_NF-kB signaling pathway 22
11.48 TNFRSF1B TNF IL1R1
22
amb2 Integrin signaling 1
11.42 TNF MMP9 ITGB2
23
Malaria 36
11.4 TNF ITGB2 CXCL8 CSF3
24
Nucleotide-binding Oligomerization Domain (NOD) pathway 1
11.35 NOD2 NLRP3 MEFV
25
IL1 and megakaryocytes in obesity 1
11.05 NLRP3 MMP9 IL1R1
26
Interleukin-10 signaling 65
10.79 TNFRSF1B TNF IL1RN IL1R1 CXCL8 CSF3
Sources

GO Terms for Pyoderma Gangrenosum

About this section

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 TNF MMP9 IL1RN IFNA2 F3 CXCL8
2 cell surface GO:0009986 9.5 TNF NOD2 ITGB2 IL1R1 F3 CCR6
3 extracellular region GO:0005576 9.44 TNFRSF1B TNF NLRP3 MMP9 MMP26 IL1RN

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.88 TNF MMP9 MMP26 ITGB2
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF NOD2 NLRP3 ITGB2
3 defense response GO:0006952 9.77 TNF NOD2 NLRP3 IFNA2 CXCL8
4 immune response GO:0006955 9.76 TNFRSF1B TNF IL1RN IL1R1 CXCL8 CSF3
5 cellular response to lipopolysaccharide GO:0071222 9.73 TNFRSF1B TNF NOD2 NLRP3 CXCL8 CSF3
6 negative regulation of inflammatory response GO:0050728 9.72 TNFRSF1B NLRP3 MVK MMP26 MEFV
7 humoral immune response GO:0006959 9.71 TNF IFNA2 CCR6
8 regulation of inflammatory response GO:0050727 9.71 TNF NOD2 NLRP3 IL1R1
9 inflammatory response GO:0006954 9.65 TNFRSF1B TNF PSTPIP1 NLRP3 MEFV ITGB2
10 regulation of neuroinflammatory response GO:0150077 9.57 TNFRSF1B MMP9
11 leukocyte migration involved in inflammatory response GO:0002523 9.56 ITGB2 CCR6
12 cellular response to peptidoglycan GO:0071224 9.55 NOD2 NLRP3
13 positive regulation of type 2 immune response GO:0002830 9.52 NOD2 NLRP3
14 cellular extravasation GO:0045123 9.51 TNF ITGB2
15 cytokine secretion involved in immune response GO:0002374 9.48 NOD2 NLRP3
16 positive regulation of prostaglandin-E synthase activity GO:2000363 9.46 NOD2 ITGB2
17 detection of biotic stimulus GO:0009595 9.43 NOD2 NLRP3
18 cytokine-mediated signaling pathway GO:0019221 9.32 TNFRSF1B TNF MMP9 ITGB2 IL1RN IL1R1

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TNFRSF1B TNF SIGLEC5 PSTPIP1 NOD2 NLRP3
2 identical protein binding GO:0042802 9.7 TNF PSTPIP1 NLRP3 MVK MMP9 MEFV
3 cytokine activity GO:0005125 9.02 TNF IL1RN IFNA2 CXCL8 CSF3
Sources

Sources for Pyoderma Gangrenosum

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....